New User:
-or-
Username:
Password:
Forgot your password?
News Breaks
14:49 EDTOPTR
theflyonthewall.com: Optimer Pharm announces presentation of new data for fidaxomicin's
Optimer Pharmaceutical announced the presentation of new data from fidaxomicin's North American phase 3 study at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia, PA. Mark A. Miller, M.D., head of the Division of Infectious Diseases, Chair of the Infection Prevention and Control Unit at the Jewish General Hospital in Montreal, Quebec, Canada, presented results showing that fidaxomicin is associated with faster resolution of diarrhea. In another presentation, Kathleen M. Mullane, D.O., an investigator from the University of Chicago, Department of Medicine, Section of Infectious Diseases, in Illinois, presented data that indicated fidaxomicin may be a more effective therapy for CDI in patients requiring concomitant antibiotics. :theflyonthewall.com



News For OPTR From The Last 14 Days
Check below for free stories on OPTR the last two weeks.
There are 3 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing.
February 5, 2010
09:44 EDTOPTR
theflyonthewall.com: Gappers report: Bullish gaps
This is a list of stocks making unusual moves on the open versus the prior day close. Gapping stocks often have excessive movements during the day and in the days thereafter. We use 5% for filter criteria and scanned for stocks that traded above $10 the prior day. GAPPING UP: TCI 5.56%, CTCT 5.86%, TSN 5.93%, HAIN 6.61%, RMD 7.99%, PKI 8.48%, LMNX 8.85%, ALKS 10.36%, FARO 10.86%, SFLY 12.30%, LRN 12.66%, OPTR 13.83%, ARG 43.92%. :theflyonthewall.com
09:27 EDTOPTR
theflyonthewall.com: Pre-market top 5 gainers

Subscribe for More Information :theflyonthewall.com

February 4, 2010
16:31 EDTOPTR
theflyonthewall.com: Optimer Pharm announces results from second Fidaxomicin Phase 3 study
Optimer Pharmaceuticals announced positive top-line results from the second of two pivotal Phase 3 trials evaluating the safety and efficacy of fidaxomicin, or OPT-80, in patients with Clostridium difficile Infection. The trial met the primary endpoint of non-inferiority with 91.7% of patients treated with fidaxomicin achieving clinical cure vs. 90.6% for Vancocin, the only FDA-approved therapy for CDI. Importantly, fidaxomicin also had significantly lower recurrence rates and higher global cure rates compared to Vancocin. :theflyonthewall.com